

LIDDS appoints Matthew Lindon as acting CEO

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that Matthew Lindon will assume the role of acting Chief Executive Officer for LIDDS, effective August 1st, 2023, succeeding Anders Månsson.

In addition to his role as Chief Scientific Officer for LIDDS, Matthew Lindon will take over the role as CEO on an interim basis from August 1st.

Matthew joined LIDDS as CSO in March 2022 with over 20 years of drug discovery and development experience in global pharmaceutical R&D from AstraZeneca, GlaxoSmithKline and Merck. Over the last twelve months he has worked closely with out-going CEO, Anders Månsson to focus LIDDS' business and drive forward a strong business development strategy.

“Matthew’s appointment is recognition of the need for continuity in executing the strategic plans developed in the last year”, says Pontus Ottosson, chairman of LIDDS. “Matthew has been central to our strategy, knows the business well, and has the right leadership capabilities to drive LIDDS forward”.

“Like many small biotech companies LIDDS has faced headwinds in recent times, and during the last months we’ve restructured the business to adapt to these challenges” says Matthew Lindon. “Despite this, I see in LIDDS a company with an effective technology in NanoZolid®, and a portfolio of clinical stage assets, with proven modes of action. We must remain focused and continue to deliver on our strategy to find partners for all of LIDDS’ assets, to maximise value in all aspects of the business”.

Anders will remain with LIDDS until August 31st to ensure a smooth transition.

For additional information, please contact

Matthew Lindon, CSO and acting CEO
Phone: +46 (0)72 207 2101
E-mail: matthew.lindon@liddspharma.com

Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS's Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

Attachments

LIDDS appoints Matthew Lindon as acting CEO